Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8642499 | 1.00 | KEAP1 (0.32) | KEAP1NFE2L2HCAR2 | |
| SCHEMBL3400715 | 0.84 | HCAR2 (0.38) | KEAP1NFE2L2HCAR2 | |
| SCHEMBL5070247 | 0.84 | HCAR2 (0.38) | KEAP1NFE2L2HCAR2 | |
| SCHEMBL3400712 | 0.84 | HCAR2 (0.38) | KEAP1NFE2L2HCAR2 | |
| SCHEMBL8644282 | 0.81 | — | — | |
| SCHEMBL8644288 | 0.81 | — | — | |
| SCHEMBL27927553 | 0.78 | NFE2L2 (0.62) | KEAP1NFE2L2HCAR2 | |
| SCHEMBL391777 | 0.77 | DGAT1 (0.36) | KEAP1NFE2L2HCAR2 | |
| SCHEMBL21521062 | 0.77 | DGAT1 (0.36) | KEAP1NFE2L2HCAR2 | |
| SCHEMBL391778 | 0.77 | DGAT1 (0.36) | KEAP1NFE2L2HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5209847-A | ULTRATHIN MEMBRANE OF POLYMETHACRYLATE OR POLYCROTONATE AND DEVICE PROVIDED WITH ULTRATHIN MEMBRANE | NIPPON OIL AND FATS CO., LTD. (JP) | 1993-05-11 | — | — | US | claimed |
| EP-3920922-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | Janssen Biotech, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020161663-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| US-10407482-B2 | Amino acid substituted molecules | ALLOZYNE, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-10202447-B2 | Antibody derivatives | MEDIMMUNE LIMITED (GB) | 2019-02-12 | — | — | US | disclosed |
| EP-2640745-B1 | BIVALENT AND BISPECIFIC ANTI-IL6/ANTI-IL23 ANTIBODIES | MEDIMMUNE LTD (GB) | 2018-11-07 | — | — | EP | disclosed |
| US-20160194391-A1 | ANTIBODY DERIVATIVES | ALLOZYNE, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20140255345-A1 | AMINO ACID SUBSTITUTED MOLECULES | ALLOZYNE, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140127209-A1 | ANTIBODY DERIVATIVES | MEDIMMUNE LIMITED (GB) | 2014-05-08 | — | — | US | disclosed |
| US-8568706-B2 | Modified human interferon-beta polypeptides | ALLOZYNE, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20080214439-A1 | AMINO ACID SUBSTITUTED MOLECULES | ALLOZYNE, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080200641-A1 | AMINO ACID SUBSTITUTED MOLECULES | ALLOZYNE, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080125347-A1 | AMINO ACID SUBSTITUTED MOLECULES | ALLOZYNE, INC. (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080096819-A1 | Amino acid substituted molecules | ALLOZYNE, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| WO-2007130453-A2 | NON-NATURAL AMINO ACID SUBSTITUTED POLYPEPTIDES | ALLOZYNE, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| US-5851422-A | Polymeric material for liquid crystal/polymer composite film, record display medium, and use thereof | DAI NIPPON PRINTING CO., LTD. (JP) | 1998-12-22 | — | — | US | disclosed |
| EP-0790289-A1 | Polymeric material for liquid crystal/polymer composite film, liquid crystal/polymer composite film, record display medium, and use thereof | DAI NIPPON PRINTING CO., LTD. (JP) | 1997-08-20 | — | — | EP | disclosed |
| EP-0421435-B1 | Ultrathin membrane of polymethacrylate or polycrotonate and device provided with ultrathin membrane | NIPPON OILS & FATS CO LTD (JP) | 1996-01-10 | — | — | EP | disclosed |
| US-5209847-A | ULTRATHIN MEMBRANE OF POLYMETHACRYLATE OR POLYCROTONATE AND DEVICE PROVIDED WITH ULTRATHIN MEMBRANE | NIPPON OIL AND FATS CO., LTD. (JP) | 1993-05-11 | — | — | US | disclosed |
| EP-0421435-A2 | Ultrathin membrane of polymethacrylate or polycrotonate and device provided with ultrathin membrane | NIPPON OIL AND FATS COMPANY, LIMITED (JP) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407482-B2 | Amino acid substituted molecules | BCAT2, DNPEP, PTMS | KEAP1 2755/4885NFE2L2 3380/4885HCAR2 367/4885 |
| US-20080096819-A1 | Amino acid substituted molecules | BCAT2, DNPEP, PTMS | KEAP1 2755/4885NFE2L2 3380/4885HCAR2 367/4885 |
| US-20080214439-A1 | AMINO ACID SUBSTITUTED MOLECULES | BCAT2, DNPEP, PTMS | KEAP1 2755/4885NFE2L2 3380/4885HCAR2 367/4885 |
| US-10202447-B2 | Antibody derivatives | IL23R, IL6, IL2 | KEAP1 2388/4885NFE2L2 2673/4885HCAR2 1875/4885 |
| US-20140255345-A1 | AMINO ACID SUBSTITUTED MOLECULES | BCAT2, DNPEP, PTMS | KEAP1 2755/4885NFE2L2 3380/4885HCAR2 367/4885 |
| US-20160194391-A1 | ANTIBODY DERIVATIVES | IL23R, IL6, IL2 | KEAP1 2460/4885NFE2L2 2833/4885HCAR2 1817/4885 |
| US-20080200641-A1 | AMINO ACID SUBSTITUTED MOLECULES | BCAT2, DNPEP, PTMS | KEAP1 2755/4885NFE2L2 3380/4885HCAR2 367/4885 |
| US-20140127209-A1 | ANTIBODY DERIVATIVES | IL23R, IL6, IL2 | KEAP1 2388/4885NFE2L2 2673/4885HCAR2 1875/4885 |
| US-20080125347-A1 | AMINO ACID SUBSTITUTED MOLECULES | BCAT2, DNPEP, PTMS | KEAP1 2755/4885NFE2L2 3380/4885HCAR2 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.